The present invention relates to methods and materials for controlling chlorogenic acid synthesis based on manipulation of hydroxycinnamoyl-CoA quinate hydroxycinnamoyl transferase (HQT) genes.
The plant phenylpropanoid pathway is responsible for the synthesis of a wide variety of secondary metabolic compounds, including lignins, salicylates, coumarins, hydroxycinnamic amides, flavonoid phytoalexins, pigments, UV light protectants and antioxidants (D
Chlorogenic acid, an ester of quinic and caffeic acid (S
The fact that chlorogenic acid is one of the initial products formed during the transcriptional activation of the phenylpropanoid pathway by pathogen infection and abiotic stress, led to the assumption that chlorogenic acid acts as a carbon reservoir. The mobilization of this pool to form downstream phenylpropanoid products such as lignins, phytoalexins and cell wall cross-linking agents would enable the plants to respond immediately to pathogen attack (Y
Recent studies proposed another potential function of chlorogenic acid in plants—as an antioxidant. Environmental stresses such as high light, UV light, low temperature and pathogen infection can all lead to an increase of reactive oxygen species in plants. To avoid lethal damage caused by these oxidative species, plants have developed a complex antioxidant system. In addition to the well-characterised system which includes enzymes such as superoxide dismutase or ascorbate peroxidase, a few studies have analysed the role of phenolic metabolites in scavenging reactive oxygen species (G
Free radicals and other reactive species are considered to be important factors in the development of cancer and cardiovascular diseases. Due to their antioxidant capacity the interest in food polyphenolics such as chlorogenic acid has increased. Food phenolics are thought to provide beneficial implications in human health, e.g. in the treatment and prevention of cancer (B
Two different pathways have been proposed for the biosynthesis of chlorogenic acid. In sweet potato the enzyme hydroxycinnamoyl-D-glucose quinate hydroxycinnamoyl transferase has been isolated (V
An alternative pathway has been proposed on the basis of chlorogenic acid biosynthesis in tobacco cell suspension cultures initially described by S
Recently, the isolation of a 3-hydroxylase from Arabidopsis, which has been shown to catalyze the formation of chlorogenic acid by hydroxylation of coumaroyl quinic acid in vitro, led to the consideration that plants may also be able to synthesize chlorogenic acid by hydroxylation (S
Although HQT has been partially purified from various plant species, particularly in Solanaceae (R
Indeed, to date 116 transferases have been identified in plants (examples include anthranilate N-hydroxycinnamoyl/benzoyl transferase, that catalyses the first committed reaction of phytoalexin biosynthesis, deacetylvindoline 4-O-acetyltransferase and trichothecene 3-O-acetyltransferase). Nevertheless, apart from the DFGWG sequence motif, there are only few conserved amino acids within the transferase family. Even within the subgroup of anthranilate N-hydroxycinnamoyl/benzoyl transferase the amino acid sequences differ so much that the enzymes from Arabidopsis and clove pink are not closely related (
In seeking to solve the problem of providing the HQT gene, the inventors originally thought the tobacco hypersensitive response protein 201 would be a good candidate for HQT because of its expression pattern during hypersensitive response after pathogen attack. Hsr201 is a member of the transferase family and shows less homology to known anthranilate transferase, which indicates a putative new function in tobacco. However, the recombinant protein expressed in E. coli showed no HQT enzyme activity (
The isolation and characterization of the gene and enzyme HQT that catalyses the synthesis of chlorogenic acid, the major antioxidant in higher plants, may contribute inter alia to improvements in the antioxidant content of food. It could further be used to modify inter alia, this and other traits in plants.
The inventors have succeeded in cloning HQT genes from plants. This is the first time a gene known to encode an HQT has been cloned.
In order to provide the HQT genes, briefly, the inventors purified HQT from tobacco leaves by using anion exchange and hydrophobic interaction chromatography (
Two partial amino acid sequences of the purified protein, obtained from Q-TOF analysis were found to match with a hydroxycinnamoyl-benzoyl transferase from sweet potato and the translation products of tobacco and tomato EST clones. By using overlapping tomato EST clones a full-length cDNA was assembled (see
Using the sequence of the EST clones the full-length cDNA clones of HQT from tobacco and tomato were isolated by using RT-PCR. The two related cDNAs encode 430 amino acids (tomHQT, calculated mass 47,960 D) and 436 amino acids (tobHQT, calculated mass of 48,390 D). The amino acid sequences show 90% homology to each other and 81-83% homology to the N-hydroxycinnamoyl/benzoyl transferase from sweet potato (accession number AB035183). Although the activity and substrate specificity of the sweet potato protein has apparently not been characterised, the classification of the protein as an N-hydroxycinnamoyl/benzoyl transferase has been made according to sequence homologies to other members of the transferase family. In the light of the disclosure herein, it appears this enzyme may also have HQT activity.
The encoded protein sequences of both cDNA clones contain the DFGWG sequence motif that is characteristic of transferases from plants and may therefore form part of the active site.
To confirm the identity of proteins as HQT the enzyme activity was analysed after expressing the cDNA from tomato in E. coli. As shown in
Increased HQT enzyme activity was also detected in leaves of Nicotiana benthamiana plants expressing high levels of tomato and tobacco HQT under the control of the 35S promoter (
In various aspects of the invention the HQT gene, or its variants, may be employed in the regulation of chlorogenic acid synthesis in a plant. Regulation of chlorogenic acid synthesis may be used inter alia to alter the flavour, palatability, texture, nutritional value or antioxidant properties of the plant.
According to an aspect of the present invention there is provided an isolated nucleic acid molecule encoding a polypeptide which has HQT activity (i.e. an HQT).
As described above, HQT catalyses the production of chlorogenic acid via transfer of the caffeoyl moiety of caffeoyl-CoA to quinic acid. Such activity can be assessed, for example, using the assay described in Example 2. Briefly, the assay uses caffeoyl CoA and quinic acid as substrates, and the rate of conversion of caffeoyl CoA to chlorogenic acid is determined by spectrophotometry.
Nucleic acid according to the present invention may include cDNA, RNA, genomic DNA and modified nucleic acids or nucleic acid analogs (e.g. peptide nucleic acid). Where a DNA sequence is specified, e.g. with reference to a figure, unless context requires otherwise the RNA equivalent, with U substituted for T where it occurs, is encompassed.
Likewise, DNA is generally found in double-stranded form, and the complementary strand of such DNA sequences is also included in the ambit of the invention. A nucleic acid is “the complement” of another nucleic acid to which it is complementary. ‘Complementary to’ means that the sequence is capable of base pairing with the coding sequence whereby A is the complement of T (and U); G is the complement of C; and may be of equal length to, or of a portion of, said DNA sequence.
Nucleic acid molecules according to the present invention may be provided in isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or free or substantially free of other nucleic acids of the species of origin. Where used herein, the term ‘isolated’ encompasses all of these possibilities. The nucleic acid molecules may be wholly or partially synthetic. In particular they may be recombinant in that nucleic acid sequences which are not found together in nature (do not run contiguously) have been ligated or otherwise combined artificially. Alternatively they may have been synthesised directly e.g. using an automated synthesiser.
Most preferably the nucleic acid is derived from tobacco or tomato. Thus included in this aspect of the invention, there are also provided nucleic acids encoding the polypeptides of
In this aspect of the present invention there are also provided nucleic acids which are variants of the said sequences. A variant nucleic acid molecule shares homology with, or is identical to, all or part of the coding sequence discussed above. Generally variants may encode, or be used to isolate or amplify nucleic acids which encode, polypeptides which have HQT activity as described above. However, variants which do not encode polypeptides having HQT activity are also provided, eg. for use in probing or silencing. Variants of the present invention can be artificial nucleic acids, which can be prepared by the skilled person in the light of the present disclosure. Alternatively they may be novel, naturally occurring, nucleic acids, isolatable using the sequences of the present invention.
Sequence variants which occur naturally may include HQT alleles (which typically include polymorphisms or mutations at one or more bases) or pseudoalleles (which may occur at closely linked loci to the HQT gene). Also included within the scope of the present invention are isogenes, or other genes homologous to the HRT sequences of the invention and belonging to the same family as the HQT gene. Although these may occur at different genomic loci to the HQT gene, they typically share conserved regions with it.
Artificial variants (derivatives) may be prepared by those skilled in the art, for instance by site directed or random mutagenesis, or by direct synthesis. Preferably the variant nucleic acid is generated either directly or indirectly (e.g. via one or more amplification or replication steps) from an original nucleic acid having all or part of the sequence shown in
Thus a variant may be a distinctive part or fragment (however produced) corresponding to a portion of the sequence provided. The fragments may encode particular functional parts of the polypeptide. Alternatively, the fragments may have utility in probing for, or amplifying, the sequence provided or closely related ones. Suitable lengths of fragment, and conditions, for such processes are discussed in more detail below.
Also included are nucleic acids corresponding to those above, but which have been extended at the 3′ or 5′ terminus.
The term ‘variant’ nucleic acid as used herein encompasses all of these possibilities. When used in the context of the present invention with regard to polypeptides or proteins, ‘variant’ indicates the encoded expression product of the variant nucleic acid.
Some of the aspects of the present invention relating to variants will now be discussed in more detail.
Similarity or homology (the terms are used interchangeably) or identity may be as defined and determined by the TBLASTN program, of Altschul et al. (1990) J. Mol. Biol. 215: 403-10, or BestFit, which is part of the Wisconsin Package, Version 8, September 1994, (Genetics Computer Group, 575 Science Drive, Madison, Wis., USA, Wisconsin 53711). Preferably sequence comparisons are made using MultAlin (see Corpet, 1988, Nucleic Acids Research 16 10881-10890). Default parameters are preferably set as follows:
Alternatively, sequence comparisons may be made using FASTA and FASTP (see Pearson & Lipman, 1988. Methods in Enzymology 183: 63-98). Parameters may be set, using the default matrix, as follows:
Homology may be at the nucleotide sequence and/or encoded amino acid sequence level. Preferably, the nucleic acid and/or amino acid sequence shares at least about 90%, 95%, 96%, 97%, 98% or 99% homology or identity.
Homology may be over the full-length of the relevant sequence shown herein, or may be over a part of it, preferably over a contiguous sequence of about or greater than about 20, 25, 30, 33, 40, 50, 67, 133, 167, 200, 233, 267, 300, 333, 400 or more amino acids or codons, compared with
Thus a variant polypeptide in accordance with the present invention may include within either of the sequences shown in
The activity of functional variant polypeptides may be assessed by transformation into a host capable of expressing the nucleic acid of the invention. Methodology for such transformation is described in more detail below.
In a further aspect of the invention there is disclosed a method of producing a derivative nucleic acid comprising the step of modifying any of the sequences disclosed above, particularly the coding sequence of
Alternatively changes to a sequence may produce a derivative by way of one or more of addition, insertion, deletion or substitution of one or more nucleotides in the nucleic acid, leading to the addition, insertion, deletion or substitution of one or more amino acids in the encoded polypeptide.
Such changes may modify sites which are required for post translation modification such as cleavage sites in the encoded polypeptide; motifs in the encoded polypeptide for glycosylation, lipoylation etc. Leader or other targeting sequences (e.g. membrane or golgi locating sequences) may be added to the expressed protein to determine its location following expression.
Other desirable mutation may be random or site directed mutagenesis in order to alter the activity (e.g. specificity) or stability of the encoded polypeptide. Changes may be by way of conservative variation, i.e. substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine. As is well known to those skilled in the art, altering the primary structure of a polypeptide by a conservative substitution may not significantly alter the activity of that peptide because the side-chain of the amino acid which is inserted into the sequence may be able to form similar bonds and contacts as the side chain of the amino acid which has been substituted out. This may be so even when the substitution is in a region which is critical in determining the conformation of the peptide. Also included are variants having non-conservative substitutions.
As is well known to those skilled in the art, substitutions to regions of a peptide which are not critical in determining its conformation may not greatly affect its activity because they may not greatly alter the peptide's three dimensional structure. In regions which are critical in determining the peptides conformation or activity such changes may confer advantageous properties on the polypeptide. Indeed, changes such as those described above may confer slightly advantageous properties on the peptide e.g. altered stability or specificity. It may be preferred to retain the putative active site motif DFGWG (amino acid residues 382-386 of the tobacco HQT nucleotide sequence of
In a further aspect of the present invention there is provided a method of identifying and/or cloning a nucleic acid variant from a plant which method employs an HQT sequence as described herein.
For instance, nucleotide sequence information provided herein may be used in a data-base (e.g. of ESTs, or STSs) search to find homologous sequences, and expression products of which can be tested for activity as described below in Example 2.
Nucleotide sequence information provided herein may be used to design probes and primers for probing or amplification of HQT or variants thereof. An oligonucleotide for use in probing or PCR may be about 32 or fewer nucleotides in length (e.g. 16, 18, 21 or 24). Generally specific primers are upwards of 14 nucleotides in length. For optimum specificity, primers of 16-32 nucleotides in length may be preferred. Those skilled in the art are well versed in the design of primers for use processes such as PCR.
Preferred primers which can be used include any of those shown in the Examples below as being suitable for amplifying HQT sequences.
If required, probing can be done with entire restriction fragments of the cDNA sequences disclosed herein, or the full-length cDNAs themselves. Fragments may be used e.g. the sequence employed may be about 100 nucleotides or more, about 200 nucleotides or more, about 300 nucleotides or more, or about 400 nucleotides or more, in each case the sequence may be a contiguous sequence selected from those nucleic acids disclosed herein.
Naturally sequences may be based on either
Such probes and primers form one aspect of the present invention.
Probing may employ the standard Southern blotting technique. For instance DNA may be extracted from cells and digested with different restriction enzymes. Restriction fragments may then be separated by electrophoresis on an agarose gel, before denaturation and transfer to a nitrocellulose filter. Labelled probe may be hybridised to the DNA fragments on the filter and binding determined. DNA for probing may be prepared from RNA preparations from cells. Probing may optionally be done by means of so-called ‘nucleic acid chips’ (see Marshall & Hodgson (1998) Nature Biotechnology 16: 27-31, for a review).
In one aspect, there is provided a method of obtaining an HQT variant nucleic acid molecule which comprises:
Test nucleic acid may be provided from a cell as genomic DNA, cDNA or RNA, or a mixture of any of these, preferably as a library in a suitable vector. If genomic DNA is used the probe may be used to identify untranscribed regions of the gene (e.g. promoters etc).
Binding of a probe to target nucleic acid (e.g. DNA) may be measured using any of a variety of techniques at the disposal of those skilled in the art. For instance, probes may be radioactively, fluorescently or enzymatically labelled. Other methods not employing labelling of probe include amplification using PCR (see below), RNase cleavage and allele specific oligonucleotide probing. The identification of successful hybridisation is followed by isolation of the nucleic acid which has hybridised, which may involve one or more steps of PCR or amplification of a vector in a suitable host.
Preliminary experiments may be performed by hybridising under low stringency conditions. For probing, preferred conditions are those which are stringent enough for there to be a simple pattern with a small number of hybridisations identified as positive which can be investigated further.
For example, hybridizations may be performed, according to the method of Sambrook et al. (below) using a hybridization solution comprising: 5×SSC (wherein ‘SSC’=0.15 M sodium chloride; 0.15 M sodium citrate; pH 7), 5×Denhardt's reagent, 0.5-1.0% SDS, 100 μg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide. Hybridization is carried out at 37-42° C. for at least six hours. Following hybridization, filters are washed as follows: (1) 5 minutes at room temperature in 2×SSC and 1% SDS; (2) 15 minutes at room temperature in 2×SSC and 0.1% SDS; (3) 30 minutes−1 hour at 37° C. in 1×SSC and 1% SDS; (4) 2 hours at 42-65° C. in 1×SSC and 1% SDS, changing the solution every 30 minutes.
One common formula for calculating the stringency conditions required to achieve hybridization between nucleic acid molecules of a specified sequence homology is (Sambrook et al., 1989): Tm=81.5° C.+16.6Log [Na+]+0.41 (% G+C)−0.63 (% formamide)−600/#bp in duplex
As an illustration of the above formula, using [Na+]=[0.368] and 50-% formamide, with GC content of 42% and an average probe size of 200 bases, the Tm is 57° C. The Tm of a DNA duplex decreases by 1−1.5° C. with every 1% decrease in homology. Thus, targets with greater than about 75% sequence identity would be observed using a hybridization temperature of 42° C. Such a sequence would be considered substantially homologous to the nucleic acid sequence of the present invention.
It is well known in the art to increase stringency of hybridisation gradually until only a few positive clones remain. For detection of sequences that are greater than about 90% identical, suitable conditions include hybridization overnight at 65° C. in 0.25M Na2HPO4, pH 7.2, 6.5% SDS, 10% dextran sulfate and a final wash at 60° C. in 0.1×SSC, 0.1% SDS.
An alternative, which may be particularly appropriate with plant nucleic acid preparations, is a solution of 5×SSPE (final 0.9 M NaCl, 0.05M sodium phosphate, 0.005M EDTA pH 7.7), 5×Denhardt's solution, 0.5% SDS, at 65° C. overnight, (for high stringency, highly similar sequences). Washes in 0.2×SSC/0.1% SDS at 65° C. for high stringency.
In a further embodiment, hybridisation of a nucleic acid molecule to a variant may be determined or identified indirectly, e.g. using a nucleic acid amplification reaction, particularly the polymerase chain reaction (PCR). PCR requires the use of two primers to specifically amplify target nucleic acid, so preferably two nucleic acid molecules with sequences characteristic of HQT are employed. Using RACE PCR, only one such primer may be needed (see “PCR protocols; A Guide to Methods and Applications”, Eds. Innis et al, Academic Press, New York, (1990)).
Thus a method involving use of PCR in obtaining nucleic acid according to the present invention may include:
The presence of an amplified PCR product may indicate identification of a variant.
In all cases above, if need be, clones or fragments identified in the search may be extended. For instance if it is suspected that they are incomplete, the original DNA source (e.g. a clone library, mRNA preparation etc.) can be revisited to isolate missing portions e.g. using sequences, probes or primers based on that portion which has already been obtained to identify other clones containing overlapping sequence. As used herein, unless the context demands otherwise, the term HQT is intended to cover any of the nucleic acids of the invention described above, including functional variants.
The methods described above may also be used to determine the presence of one of the nucleotide sequences of the present invention within the genetic context of an individual plant, optionally a transgenic plant such as may be produced as described in more detail below. This may be useful in plant breeding programmes e.g. to directly select plants containing alleles which are responsible for desirable traits in that plant species, either in parent plants or in progeny (e.g hybrids, F1, F2 etc.). Thus use of markers which can be designed by those skilled in the art on the basis of the nucleotide sequence information disclosed herein, for selection of a gene encoding a polypeptide with HQT activity, forms one part of the present invention.
As used hereinafter, all such HQT-related nucleotide sequences discussed or obtainable as described above will be referred to as “HQT nucleotide sequences” or “HQT nucleic acids” unless context demands otherwise.
In a further aspect of the present invention, HQT nucleotide sequences are in the form of a recombinant and preferably replicable vector.
‘Vector’ is defined to include, inter alia, any plasmid, cosmid, phage or Agrobacterium binary vector in double or single stranded linear or circular form which may or may not be self transmissible or mobilizable, and which can transform a prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g. autonomous replicating plasmid with an origin of replication).
Generally speaking, those skilled in the art are well able to construct vectors and design protocols for recombinant gene expression. Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. For further details see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al, 1989, Cold Spring Harbor Laboratory Press or Current Protocols in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992.
Specifically included are shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two different host organisms, which may be selected from actinomycetes and related species, bacteria and eucaryotic (e.g. higher plant, mammalian, yeast or fungal cells).
A vector including nucleic acid according to the present invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome.
Preferably the nucleic acid in the vector is under the control of, and operably linked to, an appropriate promoter or other regulatory elements for transcription in a host cell such as a microbial, e.g. bacterial, or plant cell. The vector may be a bi-functional expression vector which functions in multiple hosts. In the case of genomic DNA, this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell.
By “promoter” is meant a sequence of nucleotides from which transcription may be initiated of DNA operably linked downstream (i.e. in the 3′ direction on the sense strand of double-stranded DNA).
“Operably linked” means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is “under transcriptional initiation regulation” of the promoter.
In a preferred embodiment, the promoter is an inducible promoter.
The term “inducible” as applied to a promoter is well understood by those skilled in the art. In essence, expression under the control of an inducible promoter is “switched on” or increased in response to an applied stimulus. The nature of the stimulus varies between promoters. Some inducible promoters cause little or undetectable levels of expression (or no expression) in the absence of the appropriate stimulus. Other inducible promoters cause detectable constitutive expression in the absence of the stimulus. Whatever the level of expression is in the absence of the stimulus, expression from any inducible promoter is increased in the presence of the correct stimulus.
Thus this aspect of the invention provides a gene construct, preferably a replicable vector, comprising a promoter (optionally inducible) operably linked to a nucleotide sequence provided by the present invention, such as the HQT gene or a variant thereof.
Particularly of interest in the present context are nucleic acid constructs which operate as plant vectors. Specific procedures and vectors previously used with wide success upon plants are described by Guerineau and Mullineaux (1993) (Plant transformation and expression vectors. In: Plant Molecular Biology Labfax (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148). Suitable vectors may include plant viral-derived vectors (see e.g. EP-A-194809).
Suitable promoters which operate in plants include the Cauliflower Mosaic Virus 35S (CaMV 35S). Other examples are disclosed at pg 120 of Lindsey & Jones (1989) ‘Plant Biotechnology in Agriculture’ Pub. OU Press, Milton Keynes, UK. The promoter may be selected to include one or more sequence motifs or elements conferring developmental and/or tissue-specific regulatory control of expression. Inducible plant promoters include the ethanol induced promoter of Caddick et al (1998) Nature Biotechnology 16: 177-180.
If desired, selectable genetic markers may be included in the construct, such as those that confer selectable phenotypes such as resistance to antibiotics or herbicides (e.g. kanamycin, hygromycin, phosphinotricin, chlorsulfuron, methotrexate, gentamycin, spectinomycin, imidazolinones and glyphosate).
The present invention also provides methods comprising introduction of a construct of the invention into a plant cell or a microbial cell and/or induction of expression of a construct within such cell, by application of a suitable stimulus e.g. an effective exogenous inducer.
The invention further encompasses a host cell transformed with nucleic acid or a vector according to the present invention (e.g. comprising an HQT nucleotide sequence) especially a plant or a microbial cell. In the transgenic plant cell (i.e. transgenic for the nucleic acid in question) the transgene may be on an extra-genomic vector or incorporated, preferably stably, into the genome. There may be more than one heterologous nucleotide sequence per haploid genome.
The term “heterologous” is used broadly in this aspect to indicate that the gene/sequence of nucleotides in question (e.g. encoding HQT) have been introduced into said cells of the plant or an ancestor thereof, using genetic engineering, i.e. by human intervention. A heterologous gene may replace an endogenous equivalent gene, i.e. one which normally performs the same or a similar function, or the inserted sequence may be additional to the endogenous gene or other sequence. Nucleic acid heterologous to a plant cell may be non-naturally occurring in cells of that type, variety or species. Thus the heterologous nucleic acid may comprise a coding sequence of or derived from a particular type of plant cell or species or variety of plant, placed within the context of a plant cell of a different type or species or variety of plant. A further possibility is for a nucleic acid sequence to be placed within a cell in which it or a homologue is found naturally, but wherein the nucleic acid sequence is linked and/or adjacent to nucleic acid which does not occur naturally within the cell, or cells of that type or species or variety of plant, such as operably linked to one or more regulatory sequences, such as a promoter sequence, for control of expression.
Thus a further aspect of the present invention provides a method of transforming a host cell involving introduction of a construct as described above into a host cell and causing or allowing recombination between the vector and the host cell genome to introduce a nucleic acid according to the present invention into the genome. Preferably, the host cell will be a plant cell.
The host cell (e.g. plant cell) is preferably transformed by the construct, which is to say that the construct becomes established within the cell, altering one or more of the cell's characteristics. Nucleic acid can be introduced into plant cells using any suitable technology, such as a disarmed Ti-plasmid vector carried by Agrobacterium exploiting its natural gene transfer ability (EP-A-270355, EP-A-0116718, NAR 12(22) 8711-87215 1984), particle or microprojectile bombardment (U.S. Pat. No. 5,100,792, EP-A-444882, EP-A-434616) microinjection (WO 92/09696, WO 94/00583, EP 331083, EP 175966, Green et al. (1987) Plant Tissue and Cell Culture, Academic Press), electroporation (EP 290395, WO 8706614 Gelvin Debeyser) other forms of direct DNA uptake (DE 4005152, WO 9012096, U.S. Pat. No. 4,684,611), liposome mediated DNA uptake (e.g. Freeman et al. Plant Cell Physiol. 29: 1353 (1984)), or the vortexing method (e.g. Kindle, PNAS U.S.A. 87: 1228 (1990d) Physical methods for the transformation of plant cells are reviewed in Oard, 1991, Biotech. Adv. 9: 1-11.
Agrobacterium transformation is widely used by those skilled in the art to transform dicotyledonous species.
Recently, there has also been substantial progress towards the routine production of stable, fertile transgenic plants in almost all economically relevant monocot plants (see e.g. Hiei et al. (1994) The Plant Journal 6, 271-282)). Microprojectile bombardment, electroporation and direct DNA uptake are preferred where Agrobacterium alone is inefficient or ineffective. Alternatively, a combination of different techniques may be employed to enhance the efficiency of the transformation process, eg bombardment with Agrobacterium coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with Agrobacterium (EP-A-486233).
The particular choice of a transformation technology will be determined by its efficiency to transform certain plant species as well as the experience and preference of the person practising the invention with a particular methodology of choice. It will be apparent to the skilled person that the particular choice of a transformation system to introduce nucleic acid into plant cells is not essential to or a limitation of the invention.
Generally speaking, following transformation, a plant may be regenerated, e.g. from single cells, callus tissue or leaf discs, as is standard in the art. Almost any plant can be entirely regenerated from cells, tissues and organs of the plant. Available techniques are reviewed in Vasil et al., Cell Culture and Somatic Cell Genetics of Plants, Vol I, II and III, Laboratory Procedures and Their Applications, Academic Press, 1984, and Weissbach and Weissbach, Methods for Plant Molecular Biology, Academic Press, 1989.
The generation of fertile transgenic plants has been achieved in the cereals rice, maize, wheat, oat, and barley (reviewed in Shimamoto, K. (1994) Current Opinion in Biotechnology 5, 158-162.; Vasil, et al. (1992) Bio/Technology 10, 667-674; Vain et al., 1995, Biotechnology Advances 13 (4): 653-671; Vasil, 1996, Nature Biotechnology 14 page 702).
Plants which include a plant cell according to the invention are also provided.
In addition to the regenerated plant, the present invention embraces all of the following: a clone of such a plant, seed, selfed or hybrid progeny and descendants (e.g. F1 and F2 descendants).
A plant according to the present invention may be one which does not breed true in one or more properties. Plant varieties per se may be excluded, particularly registrable plant varieties according to Plant Breeders' Rights.
The invention also provides a plant propagule from such plants, that is any part which may be used in reproduction or propagation, sexual or asexual, including cuttings, seed and so on. It also provides any part of these plants e.g. edible leaves which includes the plant cells or heterologous DNA described above.
The invention further provides a method of influencing or affecting chlorogenic acid synthesis in a plant, the method including the step of causing or allowing expression of a heterologous HQT nucleic acid sequence as discussed above within the cells of the plant.
The step may be preceded by the earlier step of introduction of the nucleic acid into a cell of the plant or an ancestor thereof.
In a preferred embodiment of the invention, plants may be stably transformed with a vector containing a HQT nucleotide sequence to increase chlorogenic acid synthesis within the plant's cells. Alternatively, transient expression of HQT in a plant may be achieved by, for example, infiltration of plant tissues with Agrobacterium tumefaciens containing a vector comprising a HQT nucleotide sequence. Non-limiting demonstration of both transient and stable expression is given below. For example, the inventors have stably transformed tobacco and tomato plants with a binary vector containing the cDNA of HQT from tobacco and tomato under the control of the double 35S promoter (Example 8). They have also demonstrated transient expression of HQT and concomitant increase in chlorogenic acid production in leaves of Nicotiana benthamiana, as set forth in Example 9.
Increasing chlorogenic acid production in stable transformed plants, preferably tobacco and tomato, may improve their antioxidant content, which is of significance for plants and also for nutrition. Plants overexpressing HQT may be produced and analysed under different environmental conditions, in order to address the antioxidant function of HQT in tomato and tobacco. Other traits which may be influenced include pathogen resistance and abiotic stress.
The foregoing discussion has been generally concerned with uses of the nucleic acids of the present invention for production of functional polypeptides, thereby increasing the amount of chlorogenic acid produced and hence the level of chlorogenic acid activity.
However the information disclosed herein may also be used to reduce chlorogenic acid activity by down-regulation of HQT in cells in which it is desired to do so, thereby having the opposite effect. This may be desirable, for example, for altering texture or palatability of a host plant.
Down-regulation of HQT expression may, for instance, be achieved using anti-sense technology.
In one embodiment, antisense technology may be used to down-regulate HQT expression to inhibit flux to chlorogenic acid so that there will be an increase in ferulic acid which, if cross-linked in the cell walls, will give rise to firmer, crunchier, better-textured plant tissues.
As with plants overexpressing HQT, plants in which HQT expression is downregulated may be produced and analysed under different environmental conditions to investigate the antioxidant function of HQT in plants.
In using anti-sense genes or partial gene sequences to down-regulate gene expression, a nucleotide sequence is placed under the control of a promoter in a “reverse orientation” such that transcription yields RNA which is complementary to normal mRNA transcribed from the “sense” strand of the target gene. See, for example, Rothstein et al, 1987; Smith et al,(1988) Nature 334, 724-726; Zhang et al,(1992) The Plant Cell 4, 1575-1588, English et al., (1996) The Plant Cell 8, 179-188. Antisense technology is also reviewed in Bourque, (1995), Plant Science 105, 125-149, and Flavell, (1994) PNAS USA 91, 3490-3496.
Thus, as described above, a nucleotide sequence which is complementary to any of those coding sequences disclosed above forms a further aspect of the present invention.
An alternative to anti-sense is to use a copy of all or part of the target gene inserted in the sense orientation, to achieve reduction in expression of the target gene by co-suppression. See, for example, van der Krol et al., (1990) The Plant Cell 2, 291-299; Napoli et al., (1990) The Plant Cell 2, 279-289; Zhang et al., (1992) The Plant Cell 4, 1575-1588, and U.S. Pat. No. 5,231,020. Further refinements of the co-suppression technology may be found in WO95/34668 (Biosource); Angell & Baulcombe (1997) The EMBO Journal 16,12:3675-3684; and Voinnet & Baulcombe (1997) Nature 389: pg 553.
Another alternative to antisense is ‘gene silencing’ by RNA interference (RNAi), in which double stranded RNA (dsRNA) is used to block gene expression. The dsRNA is cleaved into fragments known as interfering RNAs (iRNAs), which direct the degradation of mRNAs with the same sequence as the iRNAs. Hence, dsRNA comprising the sequence of a target gene can be used to prevent expression of that gene.
For gene silencing of HQT, the inventors have cloned parts of the cDNA of HQT in an iRNA binary vector using the G
Further options for down regulation of gene expression include the use of ribozymes, e.g. hammerhead ribozymes, which can catalyse the site-specific cleavage of RNA, such as mRNA (see e.g. Jaeger (1997) ‘The new world of ribozymes’ Curr Opin Struct Biol 7:324-335, or Gibson & Shillitoe (1997)‘Ribozymes: their functions and strategies for their use’ Mol Biotechnol 7: 242-251.)
The complete sequence corresponding to the coding sequence (in reverse orientation for anti-sense) need not be used. For example fragments of sufficient length may be used. It is a routine matter for the person skilled in the art to screen fragments of various sizes and from various parts of the coding sequence to optimise the level of anti-sense inhibition. It may be advantageous to include the initiating methionine ATG codon, and perhaps one or more nucleotides upstream of the initiating codon. A further possibility is to target a conserved sequence of a gene, e.g. a sequence that is characteristic of one or more genes, such as a regulatory sequence.
The sequence employed may be about 500 nucleotides or less, possibly about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, or about 100 nucleotides. It may be possible to use oligonucleotides of much shorter lengths, 14-23 nucleotides, although longer fragments, and generally even longer than about 500 nucleotides are preferable where possible, such as longer than about 600 nucleotides, than about 700 nucleotides, than about 800 nucleotides, than about 1000 nucleotides or more.
It may be preferable that there is complete sequence identity in the sequence used for down-regulation of expression of a target sequence, and the target sequence, although total complementarity or similarity of sequence is not essential. One or more nucleotides may differ in the sequence used from the target gene. Thus, a sequence employed in a down-regulation of gene expression in accordance with the present invention may be a wild-type sequence (e.g. gene) selected from those available, or a variant of such a sequence.
The sequence need not include an open reading frame or specify an RNA that would be translatable. It may be preferred for there to be sufficient homology for the respective anti-sense and sense RNA molecules to hybridise. There may be down regulation of gene expression even where there is about 5%, 10%, 15% or 20% or more mismatch between the sequence used and the target gene. Effectively, the homology should be sufficient for the down-regulation of gene expression to take place.
Thus the present invention further provides the use of the nucleotide sequence of
Anti-sense or sense regulation may itself be regulated by employing an inducible promoter in an appropriate construct.
The present invention also encompasses the expression product of any of the coding (sense) nucleic acid sequences disclosed above, and methods of making the expression product by expression from encoding nucleic acid therefore under suitable conditions, which may be in suitable host cells.
Following expression, the product may be isolated from the expression system (e.g. microbial) and may be used as desired.
Preferably, the product will have the sequence of one of the polypeptides shown in
Purified HQT or variant protein, produced recombinantly by expression from encoding nucleic acid therefor, may be used to raise antibodies employing techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and might be screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al, 1992, Nature 357: 80-82). Antibodies may be polyclonal or monoclonal. As an alternative or supplement to immunising a mammal, antibodies with appropriate binding specificity may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047.
Specific binding members such as antibodies and polypeptides including antigen binding domains of antibodies that bind and are preferably specific for HQT or variant or derivative thereof represent further aspects of the present invention, as do their use and methods which employ them.
All documents cited herein are hereby incorporated by reference inasmuch as is required for the skilled person to carry out the invention.
The invention will now be further described with reference to the following non-limiting Figures and Examples. Other embodiments of the invention will occur to those skilled in the art in the light of these.
The consensus sequence of the CoA-transferase family (‘cons’) is shown below the HQT sequences. The conserved amino acid motif which is involved in the interaction with the CoA moiety of the substrate is boxed.
Enzyme Extraction and Purification
200 g frozen leaf material from Nicotiana tabacum Samsun NN was ground to a homogenous powder in liquid nitrogen using mortar and pestle. All further purification steps were carried out at 4° C.
The powder was then transferred to 600 ml extraction buffer (0.1 M K-Pi buffer containing 1.8% PVPP, 1% PEG 6000, 1.2% ascorbic acid, 20 μg ml−1 α2-macroglobulin and 5 mM DTT) and stirred until a homogenous solution was obtained. After shaking for 20 min the slurry was passed through a double layer of Miracloth and the filtrate was centrifuged at 25,000 g for 30 min. The supernatant was stirred for 20 min with 10% Dowex 1×2 100-200 which had previously been equilibrated with 0.1 M K-Pi buffer containing 1.2% ascorbic acid, 1% PEG 6000 and 5mM DTT. After centrifugation at 13,000 g for 10 min protamine sulphate (0.1 mg per 1 mg protein) was added to the supernatant. The slurry was then stirred for 20 min and the precipitated protein was collected by centrifugation (30 min at 25,000 g).
The supernatant was made up to 30% satn with finely ground (NH4)2SO4 and stirred for 30 min. The resultant precipitated protein was then removed by centrifugation for 30 min at 25,000 g and the supernatant was raised to 80% satn.
After stirring for 30 min the precipitated protein was pelleted by centrifugation at 25,000 g for 1 h and the pellet was dissolved in 100 ml 10 mM Tris-HCl buffer pH 7.5 containing 5 mM DTT. The protein solution was desalted by dialysis against 10 mM Tris-HCl buffer pH 7.5 overnight.
The protein extract was chromatographed on a DEAE-sepharose (Pharmacia) column (26 cm×2.6 cm), which had been equilibrated with 10 mM Tris-HCl buffer pH 7.5. A gradient of 0-1M KCl in 10 mM Tris-HCl pH 7.5 was applied at a flow rate of 1 ml min−1 and 10 ml fractions were collected. The fraction with the highest enzyme activity was dialysed against 10 mM Tris-HCl pH7.5 for 4 h and then applied to a MonoQ (Pharmacia) column (1 ml), pre-equilibrated in 10 mM Tris-HCL pH 7.5. The proteins were eluted by applying a gradient of 0-600 mM KCL in 10 mM Tris-HCl pH7.5 at a flow rate of 0.5 ml min−1 and 1 ml samples were collected. The two fractions with the highest enzyme activity were pooled and diluted 1:10 with 10 mM Tris-HCl pH 7.5 to reduce the salt concentration. After application onto a MonoQ column the proteins were eluted using a gradient of 0-300 mM KCl in 10 mM Tris-HCl at a flow rate of 0.5 ml min−1 and 1 ml fractions were collected. The fraction with the highest enzyme activity was diluted 1:10 with 10 mM Tris-HCl pH 7.5 containing 1.7 M (NH4)2SO4. The protein extract was then chromatographed on a phenylsucrose (Pharmacia) column (1 ml), pre-equilibrated in 10 mM Tris-HCl pH 7.5/1.7 M (NH4)2SO4, using a 0-100 10 mM Tris-HCl pH 7.5 gradient at a flow rate of 0.25 ml min−1 and 1 ml fractions were collected. The fraction with the highest enzyme activity was concentrated and desalted for polyacrylamide gel electrophoresis (SDS-PAGE) using Microcon YM-10 centrifugal filter devices (Millipore) pH 7.5.
SDS-PAGE was carried out using Tris-glycine pH 8.5 as the buffer system with a 10% acrylamide gel (L
Enzyme Activity
The enzyme activity was determined by spectrophotometry at 30° C. The reaction mixture contained in a total volume of 1 ml: 100 mM Na-Pi buffer pH 7.0, 1 mM EDTA, 16.8 μM caffeoyl CoA and 10-50 μl protein extract. After initiation of the reaction by addition of 2 mM quinic acid the change of caffeoyl CoA into chlorogenic acid could be determined by measuring the rate of decrease in absorbance at 346 nm per minute over a period of 5-10 min. The extinction coefficient for caffeoyl CoA is 1.8×104 M−1 cm−1 (Z
Characterisation of HQT Enzyme Reaction Product Chlorogenic Acid
The reaction mixture was acidified to pH 2.0 with HCl and then extracted twice with 5 ml ethylacetate. After evaporation under vacuum at 40° C. the pellet was dissolved in 200 μl 50% methanol and injected into the HPLC apparatus. The HPLC analysis was carried out as previously described (W
Isolation of Full-Length cDNA of HQT by RT-PCR and 3′ RACE
To isolate the full-length cDNA of HQT from tomato RT-PCR was carried out using the oligonucleotide B26: 5′-GACTCGAGTCGACATCGA(dT)17-3′ for the RT reaction (F
5 μg total RNA isolated from tomato leaves was used for the RT reaction which was carried out using the SUPERSCRIPT™ First-Strand Synthesis System according to the procedures provided by the manufacturer (GIBCO BRL).
The PCR reaction was conducted at 94° C. for 40 sec, 55° C. for 2 min, 72° C. for 3 min in 40 cycles, and 72° C. for 10 min. The reaction mixture contained 10 μl RT-reaction mixture (1:50 diluted), 1×reaction buffer without MgSO4, 0.2 mM dNTPs, 0.25 μM EST tom U, 0.25 μM EST tom L, 5% DMSO, 3 mM MgSO4 and 2.5 U Pwo DNA-Polymerase (Roche) in a final volume of 100 μl.
The isolation of the cDNA of HQT from tobacco was conducted in two steps:
The 3′-RACE-PCR reaction was conducted at 94° C. for 40 sec, 55° C. for 2 min, 72° C. for 3 min in 40 cycles, and 72° C. for 10 min. The reaction mixture contained 10 μl RT-reaction mixture (1:50 diluted), 1×reaction buffer without MgSO4, 0.2 mM dNTPs, 0.25 μM EST tob inter, 0.25 μM B25, 2 mM MgSO4 and 2.5 U Pwo DNA-Polymerase (Roche) in a final volume of 100 μl. The PCR products were diluted 500-fold and they were then used in a second PCR reaction, which was carried out using the nested oligonucleotide EST tob inter2 and B25 under the some conditions.
To amplify the N-terminal part of the cDNA, a PCR reaction was conducted at 94° C. for 40 sec, 45° C. for 2 min, 72° C. for 2 min in 10 cycles, followed by 30 cycles at 94° C. for 40 sec, 55° C. for 2 min, 72° C. for 2 min, and finally at 72° C. for 10 min. The reaction mixture contained 10 μl RT-reaction mixture (1:50 diluted), 1×reaction buffer without MgSO4, 0.2 mM dNTPs, 0.25 μM EST tob inter2 L, 0.25 μM EST tom U, 3 mM MgSO4, 5% DMSO and 2.5 U Pwo DNA-Polymerase (Roche) in a final volume of 100 μl.
After cloning of the PCR products into the plasmid pGEM®T easy, according to the procedures provided by the manufacturer (Promega), the products were sequenced using the ABI Prism™ Dye Terminator Cycle Sequencing Ready Reaction Kit according to the procedures provided by the manufacturer (Perkin Elmer).
The full-length cDNA of HQT from tobacco was obtained by assembling the two PCR products using the HindIII site that had been introduced within the sequence of the oligonucleotides used in the PCR reaction.
Recombinant Expression of HQT in E. coli
The full-length cDNA of HQT from tomato was subcloned in frame into the NcoI and BamHI-sites of the expression vector pSTAG under the control of the T7 RNA-Polymerase promoter. This strategy led to the introduction of a sequence encoding an S-TAG at the 5′-end of the cDNA. According to procedures provided by the manufacturer (Novagen), the expression and purification of the fusion protein was carried out using the S-TAG™ Thrombin Purification Kit. The enzyme activity of the purified protein was then analysed in HQT enzyme assays.
HPLC of Soluble Phenolics in Nicotiana benthamiana Leaves
Soluble phenolics were extracted by vortexing 30 mg of frozen, powdered leaf material in 300 μl of 70% methanol. After addition of 100 μl distilled water, the extract was vortexed again and then spun for 10 sec at 13,000 g to pellet the debris. The supernatant was analysed by gradient HPLC (apparatus from Spectra Physics, San Jose, Calif.) using a Columbus 5-μm C18 column (25 cm×4.6 mm; Phenomenex, Macclesfiled, Cheshire, UK). Solvent A was 1 mM trifluoroacetic acid, solvent B was acetonitrile, and the gradient was run for 65 min at flow rate of 1 ml min−1 with the following concentrations: 0 min :100% A, 0% B; 50 min: 60% A, 40% B; 60 min: 30% A, 70% B; 65 min: 100% A, 0% B. The column eluant was monitored using a Spctra Fous scanning detector (Spectra Physics). A chlorogenic acid standard (Sigma) was used to quantify the amount of chlorogenic acid in the leaf extracts.
Constructs for Overexpression and Gene Silencing of HQT in Plants
For overexpression of HQT, the full-length cDNA of HQT from tomato and tobacco was subcloned in frame into the NcoI and SmaI-sites of the expression vector pJIT166 (available from JIC) under the control of the double 35S-promoter. The expression cassette containing the promoter, the cDNA and the CaMV terminator was then cloned in the binary vector pBIN19 (BEVAN, 1984). The obtained constructs pTom and pTob were used for transient and stable transformation of tomato and tobacco plants in order to achieve overexpression of HQT
For gene silencing of HQT, to obtain iRNA constructs 600 bp cDNA-fragments of HQT from tobacco and tomato were amplified by PCR using the oligonucleotides G-tom sil U: 5′-GGGGACAAGTTTGTACAAAAAAGCAGGCTCAGATTACTCGTTTCAAGTGTGGC-3,′, G-tom sil L: 5′-GGGGACCACTTTGTACAAGAAAGCTGGGTTGATAA ATCAGGTTGT AATTCGAGG-3′ (corresponding to the nucleotides 424 to 447 and 1020 to 1044 of the tomato cDNA clone) and G-tob sil U: 5′-GGGGACAAGTTTGTACAAAAAAGCAGGCTCAAATGTGGTGGAGTTTCACTG-3′, G-tob sil L: 5′-GGGGACCACTTTGTACAAGAAAGCTGGGTCGGGCAGT AATTCGAGGTAATC (corresponding to the nucleotides 438 to 460 and 1034 to 1056 of the tobacco cDNA clone). The cloning of the PCR fragments into the vector pDONR201 was carried out using the G
Stable Transformation of Tobacco and Tomato Plants
The pBIN19-derivatives pTom and pTob, which contain the full-length cDNA of HQT from tomato and tobacco under the control of the double 35S, and the iRNA constructs pFRN-tom and pFRN-tob were transferred to Agrobacterium tumefaciens LBA 4404 (H
Transient Expression of HQT in Leaves of Tobacco Plants
After the transfer of the overexpression constructs pTom and pTob, and the iRNA constructs pFRNtom and pFRN-tob to Agrobacterium tumefaciens C58C1 (DEBLAERE et al., 1985) single colonies were used for growing 50 mL overnight cultures. Additional 50 ml overnight cultures of Agrobacterium tumefaciens C58C1 containing expression constructs of the green fluorescent protein (PGFP) or the gene silencing inhibitor protein 19 (p19; kindly provided by O. Vionnet) or the empty binary vectors pBIN19 and pFRN were also grown. The cells were precipitated by centrifugation at 4000 g for 20 min and resuspended in 50 ml 10 mM MgCl2. After addition of 50 μl 100 mM acetosyringene the cells were incubated at room temperature overnight. To overexpress HQT similar amounts of the cultures containing pGFP, pTom, pTob were mixed with the same volume of cultures containing either pBIN19 or p19 and each mixture was used to infiltrate three leaves of a Nicotiana benthamiana plant. After 4 days, when the expression of GFP could be monitored under UV light, the leaf material was collected and used for quantification of the chlorogenic acid content by HPLC analysis. For gene silencing the cultures containing pFRN-tom, pFRN-tob and pFRN were used to infiltrate three leaves of Nicotiana benthamiana. After 7 days the leaf material was collected and also analysed by HPLC to measure the chlorogenic acid content.
Number | Date | Country | Kind |
---|---|---|---|
0214406.1 | Jun 2002 | GB | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/GB03/02645 | 6/17/2003 | WO | 9/8/2005 |